

**Koen De Geest, MD**

**Articles:**

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol.* 2011 May 1;121(2):264-8. Epub 2011 Feb 1. PubMed PMID: 21277623; PubMed Central PMCID: PMC3081997. <http://dx.doi.org/10.1016/j.ygyno.2010.12.358>

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. *Gynecol Oncol.* 2011 Jun 1;121(3):455-61. Epub 2011 Mar 17. PubMed PMID: 21414654; PubMed Central PMCID: PMC3100412. <http://dx.doi.org/10.1016/j.ygyno.2011.02.013>

Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. *Gynecol Oncol.* 2011 Jul;122(1):89-94. Epub 2011 May 6. PubMed PMID: 21529904; PubMed Central PMCID: PMC3110746. <http://dx.doi.org/10.1016/j.ygyno.2011.03.013>

Shamshirsaz AA, Buekers T, Degeest K, Bender D, Zamba G, Goodheart MJ. A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival. *Int J Gynecol Cancer.* 2011 Oct;21(7):1232-40. PubMed PMID: 21720254. DOI: 10.1097/IGC.0b013e318220fc46

Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: reviving progesterone therapy in the molecular age. *Discov Med.* 2011 Sep;12(64):205-12. Review. PubMed PMID: 21955848

**Scholarly Publications**  
**Department of Obstetrics and Gynecology**  
**University of Iowa, Iowa City, IA**

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. *N Engl J Med*. 2012 Feb 16;366(7):610-8. PubMed PMID: 22335738; PubMed Central PMCID: PMC3296780.

<http://dx.doi.org/10.1056/NEJMoa1110352>

Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2012 Jun;125(3):635-9. Epub 2012 Mar 22. PubMed PMID: 22446624.

<http://dx.doi.org/10.1016/j.ygyno.2012.03.023>

Clevenger L, Schrepf A, Christensen D, Degeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. *Brain Behav Immun*. 2012 Apr 21. [Epub ahead of print] PubMed PMID: 22543257. <http://dx.doi.org/10.1016/j.bbi.2012.04.003>

Engle DB, Connor JP, Morris PC, Bender DP, De Geest K, Ahmed A, Goodheart MJ. Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. *Arch Gynecol Obstet*. 2012 May 9. [Epub ahead of print] PubMed PMID: 22569711.

<http://dx.doi.org/10.1007/s00404-012-2351-1>

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S. Endometrial cancer. *Obstet Gynecol Clin North Am*. 2012 Jun;39(2):255-68. PubMed PMID: 22640714. <http://dx.doi.org/10.1016/j.obgc.2012.04.001>

<http://dx.doi.org/10.1016/j.obgc.2012.04.001>

Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. *J Clin Oncol*. 2012 Jul 2. [Epub ahead of print] PubMed PMID: 22753905. <http://dx.doi.org/10.1200/JCO.2011.41.2528>

Shelton DN, Fornalik H, Neff T, Park SY, Bender D, Degeest K, Liu X, Xie W, Meyerholz DK, Engelhardt JF, Goodheart MJ. The Role of LEF1 in Endometrial Gland Formation and Carcinogenesis. *PLoS One*. 2012;7(7):e40312. Epub 2012 Jul 6. PubMed PMID: 22792274; PubMed Central PMCID: PMC3391280. <http://dx.doi.org/10.1371/journal.pone.0040312>

Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmouh L, Zimmerman MB, Penedo FJ, Lucci JA 3rd, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AK. Social Influences on Clinical Outcomes of Patients With Ovarian Cancer. *J Clin Oncol*. 2012 Jul 16. [Epub ahead of print] PubMed PMID: 22802321.

<http://dx.doi.org/10.1200/JCO.2011.39.4411>

### **Book Chapters:**

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S. Endometrial Cancer. *Obstetrics and Gynecology Clinics of North America*. Update on Gynecologic Oncology. Volume 39, 2012

### **Abstracts:**

Bottsford-Miller J, Lutgendorf S, Pecot C, Stone R, Nick A, Matsuo K, King E, De Geest K, Sood A. True blood: Platelets as a biomarker of ovarian cancer recurrence. SGO meeting abstract #134, *Gynecol Oncol* 120 Suppl 1 S57-58, 2011

Moore KN, Sill M, Miller DS, DiSilvestro P, De Geest K, Rose PG, Cardenas HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) in woman with locally advanced cervical cancer (CXCA): a GOG study. ASCO abstract # 84396, 2011

Ahmed A, Collins K, De Geest K, Bender D, Goodheart M,, Lucci J, Mendez L, Penedo F, Sood A, Lutgendorf S. Non-cancer life stressors contribute to decreased quality of life in ovarian cancer patients. SGO abstract 283, *Gynecol Oncol* 125 Suppl 1, S118, 2012

Zand B, Bottsford-Miller J, Nick A, HU w, Stone R, De Geest K, Lutgendorf s, Sood A. Metabolism gone awry: How ovarian cancer's metabolism differs from the normal ovary. SGO abstract 318, *Gynecol Oncol* 125 Suppl 1, S131, 2012

Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada S, De Geest K, Gershenson D. Bevacizumab shows activity in treating recurrent sex-cord stromal ovarian tumors: Results of a phase II trial of the Gynecologic oncology Group. SGO Late –Breaking abstract 2, *Gynecol Oncol* 2012